Raymond James Financial Services Advisors, Inc. Immuno Gen, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$66.3 Billion
Q1 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$12.46 - $29.95 $35,996 - $86,525	-2,889 Reduced 9.3%	28,191 $835,000
Q3 2023 Oct 24, 2023	SELL	$14.09 - $19.87 $22,093 - $31,156	-1,568 Reduced 4.8%	31,080 $493,000
Q2 2023 Jul 25, 2023	SELL	$3.75 - $20.05 $83,591 - $446,934	-22,291 Reduced 40.57%	32,648 $616,000
Q1 2023 Apr 14, 2023	BUY	$3.67 - $4.92 $17,733 - $23,773	4,832 Added 9.64%	54,939 $210,000
Q4 2022 Feb 08, 2023	BUY	$4.55 - $6.31 $133,137 - $184,636	29,261 Added 140.37%	50,107 $248,000

Q3 2022 Oct 25, 2022	BUY	$4.48 - $6.47 $3,875 - $5,596	865 Added 4.33%	20,846 $100,000
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $20,286 - $37,094	-6,440 Reduced 24.37%	19,981 $90,000
Q1 2022 May 11, 2022	BUY	$4.26 - $7.48 $19,374 - $34,019	4,548 Added 20.79%	26,421 $126,000
Q4 2021 Feb 08, 2022	SELL	$4.75 - $7.5 $2,356 - $3,720	-496 Reduced 2.22%	21,873 $162,000
Q3 2021 Nov 02, 2021	SELL	$5.02 - $6.59 $5,933 - $7,789	-1,182 Reduced 5.02%	22,369 $127,000
Q2 2021 Aug 11, 2021	SELL	$5.79 - $8.6 $19,680 - $29,231	-3,399 Reduced 12.61%	23,551 $155,000
Q1 2021 May 14, 2021	SELL	$6.5 - $10.53 $14,748 - $23,892	-2,269 Reduced 7.77%	26,950 $218,000
Q4 2020 Feb 12, 2021	BUY	$3.7 - $7.66 $41,998 - $86,948	11,351 Added 63.53%	29,219 $188,000
Q3 2020 Nov 04, 2020	BUY	$3.45 - $4.89 $1,697 - $2,405	492 Added 2.83%	17,868 $64,000
Q2 2020 Jul 17, 2020	SELL	$3.32 - $5.34 $3,213 - $5,169	-968 Reduced 5.28%	17,376 $80,000
Q1 2020 Apr 21, 2020	BUY	$2.12 - $6.8 $2,533 - $8,126	1,195 Added 6.97%	18,344 $63,000
Q4 2019 Feb 12, 2020	SELL	$2.25 - $5.8 $1,543 - $3,978	-686 Reduced 3.85%	17,149 $88,000
Q3 2019 Nov 07, 2019	BUY	$2.22 - $3.39 $2,555 - $3,901	1,151 Added 6.9%	17,835 $43,000
Q2 2019 Aug 06, 2019	BUY	$1.8 - $3.3 $1,609 - $2,950	894 Added 5.66%	16,684 $36,000
Q1 2019 May 06, 2019	BUY	$2.41 - $5.91 $532 - $1,306	221 Added 1.42%	15,790 $43,000
Q4 2018 Feb 11, 2019	SELL	$3.94 - $9.7 $6,351 - $15,636	-1,612 Reduced 9.38%	15,569 $75,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $10,904 - $14,277	1,268 Added 7.97%	17,181 $163,000
Q2 2018 Jul 30, 2018	SELL	$9.52 - $12.15 $191,856 - $244,858	-20,153 Reduced 55.88%	15,913 $155,000
Q1 2018 Apr 16, 2018	BUY	$6.7 - $12.95 $160,679 - $310,566	23,982 Added 198.46%	36,066 $379,000
Q4 2017 Feb 09, 2018	SELL	$5.07 - $7.92 $53,559 - $83,666	-10,564 Reduced 46.64%	12,084 $77,000
Q3 2017 Oct 26, 2017	BUY	$5.4 - $8.47 $26,686 - $41,858	4,942 Added 27.91%	22,648 $173,000
Q2 2017 Aug 15, 2017	BUY	N/A	17,706	17,706 $126,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account